A frequent need for re-ablations and limited overall success rates are still major limitations of catheter ablation procedures for the treatment of atrial fibrillation (AF). These limitations include not only the durability of the pulmonary vein isolation (PVI) lines, but also the pathophysiological understanding of the arrhythmia's substrate. Long-term single procedure success rates in non-paroxysmal AF are disappointingly low for current stepwise ablation approaches adding the placement of linear lines and electrogram-based ablation after circumferential PVI isolation. In the future, substrate modification in AF ablation should move toward individualized patient-tailored ablation procedures. Magnetic resonance imaging could play a major role for noninvasively describing the localization and extent of fibrotic areas. Specific new strategies that could be used include precise localization and ablation of rotors that maintain the arrhythmia using multielectrode mapping during AF and box isolation of fibrotic areas guided by electroanatomic voltage mapping during sinus rhythm. (J Am Coll Cardiol 2015;65:196-206)
Circumferential pulmonary vein isolation (PVI), with confirmation of the entrance block, anchors this procedure. However, this intervention produces a frequent need for re-ablations and has limited overall success rates. This is caused by limitations not only in the durability of PVI lines, but also in our current understanding of the pathophysiology, especially of the arrhythmia's substrate.
A better understanding of the human atrial substrate that maintains AF has led to the concept of pre-existing specific fibrotic atrial cardiomyopathy (FACM), in which AF manifests from an individually localized substrate (2, 3) . This may help explain why circumferential PVI is effective in many, but not all, patients with paroxysmal AF, and is also effective in some patients with long-standing, persistent AF. In addition, the extent and localization of an individual patient's AF substrate must be understood to find effective ablation targets in the relatively small group of people with paroxysmal AF who experience AF recurrences despite durable PVI, as well as in the larger group of patients with persistent AF who obviously need more than PVI.
HUMAN AF SUBSTRATE
In a substantial subgroup of patients, evidence suggests that there is a genetic predisposition for development of AF based on the identification of multiple genes and genetic loci that appear to affect AF susceptibility (4) . Although familial AF may be a monogenetic disorder, nonfamilial AF may be a multigenetic disease in which genetic factors interact with environmental variables. We are beginning to see research that focuses on primary fibrotic atrial changes. A recent study described a rare autosomal recessive atrial cardiomyopathy that clinically presented with atrial arrhythmias, including AF, bi-atrial dilatation, and potential electrical standstill over time, all of which were characterized by progressive fibrosis and/or scarring of the atrial myocardium (5).
Fibrotic atrial structural remodeling has been consistently described in AF patients in histological and autopsy studies (6) (7) (8) (Figure 1) . The presence of (micro)fibrosis leading to changes in cellular coupling results in spatial "nonuniform anisotropic" impulse propagation, which is a potential cause of atrial activation abnormalities underlying the initiation and perpetuation of re-entrant arrhythmias like AF (9,10).
Recent clinical research has highlighted the presence of atrial tissue fibrosis using delayed-enhancement magnetic resonance imaging (DE-MRI) and electroanatomic voltage mapping (EAVM) (11) (12) (13) (14) . Importantly, fibrotic atrial changes vary in localization and extent, and are principally bi-atrial findings. A higher mean value of fibrosis was detected in patients with persistent AF versus paroxysmal AF; however, variability in the extent of fibrosis among patients with AF is very high (7) . In addition, patients with socalled "lone" AF may exhibit a substantial fibrotic substrate before and/or at the clinical advent of AF, whereas other patients with a decades-long history of AF do not develop a significant fibrotic substrate (3).
The most frequent manifestation combination of bi-atrial FACM was described as bradycardia/tachycardia syndrome with sick sinus node plus paroxysmal AF (2) (Figure 2) . Importantly, the extent of the fibrotic atrial substrate is variable and has been classified as FACM 0 to 3 (2,3) (Figure 3) , which corresponds to the DE-MRI study Utah classification of 1 to 4 (12) . Furthermore, the regional distribution of patchy fibrotic atrial areas varies significantly from patient to patient (Figures 4 and 5) .
In other patients, the fibrotic atrial substrate leading to increased AF susceptibility may result from severe underlying structural heart disease (e.g., mitral stenosis or hypertrophic obstructive cardiomyopathy). An EAVM study in patients with rheumatic mitral stenosis who underwent commissurotomy and who did not have a history of AF described a significantly reduced bi-atrial voltage (15). Conversely, in an EAVM series of patients with systemic hypertension plus left ventricular hypertrophy, but no history of AF, the mean right atrial voltage was identical in the hypertension and control groups (16) . In general, the impact of "classic comorbidities" among patients undergoing catheter ablation of AF seems to be overestimated, as is the role of age on the fibrotic substrate (3). In an MRI study that compared left atrial (LA) structural changes in patients with lone AF versus those with classic comorbidities, the substrate was independent of comorbidities (17) . This corresponds well with a recent autopsy study in which negligibly low amounts of fibrosis were found in older patients with a high CHA 2 DS 2 -VASc score (4.3), but who did not have a history of AF; patient age was not correlated with an increase in the extent of atrial fibrosis (8).
In addition to "substrate makers" like FACM or mitral stenosis, "modulators" influence the susceptibility of AF occurrence (e.g., obesity and/or cardiometabolic syndrome, infections and/or inflammation, surgery, and cancer).
Weight reduction with intensive risk factor management substantially changed these modulators in 1 study, and reduced AF symptom burden and severity. Changing these modulators was also beneficial for cardiac remodeling (18) . With respect to surgery, pre-operatively elevated serum markers of collagen synthesis were associated with postsurgical AF in patients without a history of AF (19) . Importantly, pre-existing LA fibrosis was significantly higher in patients who developed post-surgical AF compared with those who stayed in sinus rhythm (19) , which indicates toward the modu- (28) . These findings were then tested as target sites for catheter ablation (29) . These CFAEs, which were recorded during AF, found to be bi-atrial phenomena, and had a propensity for localization at the interatrial septum, the PVs, the LA roof, the left posteroseptal mitral annulus, and the coronary sinus ostium (29) .
The definition of the CFAEs included fractionated electrograms with $2 deflections, continuous deflections of a prolonged activation complex over a 10-s recording period, and electrograms with a short cycle length (#120 ms) averaged over a 10-s recording period (29) . Procedural endpoints included eliminating CFAE sites, converting AF to sinus rhythm in patients with paroxysmal and persistent AF, and noninducibility of AF in patients with paroxysmal AF.
In a prospective, randomized multicenter study in patients with a high burden of paroxysmal or persistent AF, combining PVI and CFAE ablation resulted in a significantly higher freedom from AF compared with either technique alone (30) .
The potential limitations of CFAE mapping include the unclear specificity of these different types of electrograms, variable definition, temporal and spatial resolution of CFAE site mapping, an extensive Circumferential PVI is the only initial ablation strategy used by our group in patients with persistent and long-standing persistent AF, but who are without substantial low-voltage areas, and it was shown to be successful in preventing further AF episodes. In the relatively conservative "Hamburg sequential ablation strategy" for patients with long-standing persistent AF, 43% of patients remained in sinus rhythm after circumferential PVI was used as the sole ablative strategy (33) . With additional CFAE ablation, left linear lesions, and superior caval vein isolation, the overall short-term success rate was reported to be 68%. During a 5-year follow-up, single and multiple ablation procedural successes were 20% and 45%, respectively. Importantly, one-half of the successes were still achieved in patients who underwent circumferential PVI alone (34) .
In contrast, an individualized substrate modification using BIFAs may be added to circumferential PVI in patients with paroxysmal AF, but who also have very substantial regional LA fibrosis detected in the first ablation session (Figure 8) . Finally, in patients with massive fibrosis (the "strawberry" in Figure 3D (11, 12, 17) . In contrast to invasive EAVM, DE-MRI seems to be an attractive noninvasive, repeatable diagnostic tool. The tissue characterization of the LA wall on DE-MRI was correlated with EAVM (11) and with the histology from surgical biopsy speci- Importantly, AF sources were analyzed to be coincidentally ablated in 45% of conventional cases (e.g., at the LA roof or near the PVs) (42) (Central Illustration).
These data might help explain why wide area PVI is more effective than more distal PVI, and especially, why patients might remain free of AF recurrences despite PV re-connection. The encouraging results obtained by elimination of patient-specific rotors were recently confirmed in a multicenter study (43) .
This promising and novel technique is currently
limited by the relatively low number of 64 basket electrodes and the nonuniform distribution of electrodes with stable contact to the atrial wall. The mapping data require propriety computational software, and the results have yet to be reproduced by others.
NONINVASIVE MAPPING OF AF. Data from simultaneous bi-atrial epicardial activation sequences during AF using noninvasive electrocardiographic imaging were published a few years ago (44). In that study, 256 electrodes were applied to the patient's torso and connected to a mapping system; patients then underwent computed tomography (CT) imaging. AF complexity increased with a longer clinical history of AF, but the complexity of nonparoxysmal AF varied widely. Recently, high-resolution images of the biatrial geometry were described using an array of 252 body surface electrodes and thoracic CT (45) . A specific signal-analysis process combined filtering, wavelet transformation, and phase mapping using surface unipolar electrograms acquired during AF.
Using this technology, PV discharges, meandering rotors, and their mutual interplay were detected, as well as drifting rotors that were not stationary for more than 2 rotations. Thus, noninvasive AF mapping may identify active sources like (stable or unstable) rotors and may help identify a patient-specific ablation strategy. One specific strategy in this direction is the precise localization and ablation of rotors that maintain the 
